Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Mortality rate at Day 28 from IP administration. Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days. After: Measure: Mortality rate at Day 28 from IP administration. (Phase 2 and 3) Description: For the current study, the primary efficacy outcome measure will be the mortality rate from IP administration. Mortality is the most clinically relevant therapeutic endpoint for this population that is on IMV. The primary endpoint will be assessed at 28-days after treatment initiation. Time frame: 28 days.
Participant count type changed
Before: Estimated. After: Actual.
Enrollment · participant count changed
Before: 644 participants (planned). After: 278 participants (actual).
Completion date type changed
Before: Estimated. After: Actual.
Primary completion date changed
Before: Dec 2024. After: 22 Jul 2024.
Recruitment status changed
Before: Suspended. After: Terminated.